echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Market From the limited supply of oxcarbazepine, look at the domestic anti-epileptic drug market pattern

    Market From the limited supply of oxcarbazepine, look at the domestic anti-epileptic drug market pattern

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Novartis issued a statement saying that its anti-epileptic drug oxcarbazepine (Qulai) has limited product supply due to the shortage of key raw materials in production
    .
    Later, Novartis has temporarily solved the risk
    of supply shortage of oxcarbazepine through resource coordination.
    So at present, what is the domestic anti-epileptic drug market structure? What kind of competitive pressure will oxcarbazepine encounter in the future?

    Analysis of the market pattern of TOP5 anti-epileptic drugs

    Analysis of the market pattern of TOP5 anti-epileptic drugs

    Epilepsy is a chronic brain disease caused by a variety of etiologies, characterized by recurrent, seizures and transient central nervous system dysfunction caused by excessive firing of brain neurons, loss of consciousness during seizures, if status epilepticus is not terminated in time, can lead to irreversible brain damage due to high fever, circulatory failure or neuronal excitotoxic damage, the disability rate and mortality rate are high
    .

    According to Frost & Sullivan's analysis, in 2016, there were 544,000 patients with status epilepticus in China, which increased to 753,000 in 2020, and it is expected that the number
    of epilepsy patients in China will exceed 1 million in 2024.
    With the gradual increase of the number of patients with epilepsy, it is expected that China's anti-epileptic drug market will reach 4.
    8 billion yuan
    in 2025.

    At present, drugs are the main means of anti-epileptic treatment, and their purpose is to control the symptoms of epilepsy and reduce the number of
    incidences.
    At present, the top five domestic anti-epileptic drugs are: valproate, levetiracetam, oxcarbazepine, pregabalin, lamotrigine, accounting for 84.
    82%
    of the market share of epilepsy drugs.

    At present, the top five domestic anti-epileptic drugs are: valproate, levetiracetam, oxcarbazepine, pregabalin, lamotrigine, accounting for 84.
    82%
    of the market share of epilepsy drugs.

    Sodium valproate

    Sodium valproate

    Developed by Abbott, sodium valproate is a fatty acid derivative that acts primarily on GABAA receptors (γ-aminobutyric acid type A receptors) and NMDA receptors (N-methyl-D-aspartate receptors).

    In 2001, sodium valproate was approved by Sanofi to enter the Chinese market
    .
    As a broad-spectrum epilepsy drug, valproate is suitable for almost all types of epilepsy and seizures, and is the first-line drug for the clinical treatment of epilepsy, but its efficacy is slightly lower than that of other new anti-epileptic drugs
    .
    Sodium valproate has been used in clinical practice for more than 50 years
    worldwide.
    In 2020, the total sales of sodium valproate in China exceeded 1.
    8 billion yuan, and sales increased steadily at a growth rate of 76% in the first half of 2021
    .
    After the patent expired, the generic drugs of Shenyang Xinma Pharmaceutical and Sichuan Creide were successively approved for marketing, seizing the market share
    of the original research.

    Levetiracetam

    Levetiracetam

    Levetiracetam was developed by UCB Belgium as a second-generation acetylcholine agonist developed by UCB for the treatment of localized and secondary generalized epilepsy
    .
    In 1999, levetiracetam was approved by the FDA in tablet form as an antiepileptic drug
    with the effect of preventing the onset of epilepsy.
    In 2017, global sales of levetiracetam reached $778 million
    .

    Levetiracetam entered the Chinese market in 2006 and is the only anti-epileptic drug that has been evaluated before the first batch of national procurement declarations, with the advantages of good tolerance and reliable efficacy, but the patient's recovery is not good in the later stage, and the recurrence rate of epilepsy is high
    .
    After the expiration of the levetiracetam patent, the products of Zhejiang Jingxin Pharmaceutical, Shenzhen Salubris Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, Zhuhai Federal Pharmaceutical and other enterprises have been approved
    one after another.
    Jingxin Pharmaceutical's levetiracetam tablets (0.
    25g) is the first product
    in China to pass the consistency evaluation of this variety.

    Oxcarbazepine

    Oxcarbazepine

    Oxcarbazepine, trade name Qulai, developed by Novartis Pharmaceuticals, is a new generation of anti-epileptic drugs, which can block voltage-dependent sodium and potassium channels in patients with epilepsy, inhibit repeated nerve firing phenomena and synaptic excitation transmission in the body, reduce the number of seizures, and is the first-line treatment drug choice
    for newly diagnosed epilepsy in adults.

    Oxcarbazepine was approved by the FDA in 2000 for the treatment of epilepsy in adults and children, and was approved for marketing
    in China in 2004.
    So far, it has been widely used
    in more than 50 countries or regions around the world.
    At present, oxcarbazepine is mainly used for monotherapy or additive therapy for simple and complex partial seizures, generalized tonic-clonic seizures, etc.
    in adults and children with epilepsy, as well as adjuvant therapy
    for refractory epilepsy.

    In 2005~2014, oxcarbazepine has maintained a rapid growth rate
    .
    In 2005, the amount of oxcarbazepine in the hospital was 2.
    49 million yuan; In 2014, the amount of drugs used rose to 120 million yuan, an increase of 46.
    5 times
    in 9 years.
    After the expiration of the oxcarbazepine patent, domestic generic drugs have also been listed one after another, and currently occupied nearly the entire market
    by Novartis, Beijing Sihuan and Wuhan Renfu.

    Pregabalin

    Pregabalin

    Developed and produced by Pfizer, pregabalin is a novel neurotransmitter γ-aminobutyric acid structural analogue that reduces the release
    of neurotransmitters by blocking voltage-dependent calcium channels.
    Clinically it is mainly used for neuralgia related to diabetic peripheral neuropathy, adjuvant treatment of partial seizures in adults, generalized anxiety disorder, neuropathic pain of myeloid injury, etc
    .
    Pregabalin is a world-selling blockbuster drug, and in 2020, the sales of pregabalin in China's urban physical pharmacy terminals exceeded 100 million yuan, a year-on-year increase of 35.
    91%.

    Pregabalin's patent exclusivity expired in June 2019, and a number of generic drug products have been listed
    in China.
    Pregabalin capsules were included in the fourth batch of centralized procurement, and 4 enterprises including Qilu Pharmaceutical, Chongqing Saiwei, China Resources Shuanghe and Kolkang Menova Pharmaceutical won the bid.

    Lamotrigine

    Lamotrigine

    Lamotrigine, developed by GlaxoSmithKline (GSK), is a triazabenzene compound
    with antifolate activity.
    Lamotrigine exerts antiepileptic effects
    by blocking sodium channels and stabilizing cell membranes, thereby preventing the release of excitatory nerve mediators such as glutamic acid.
    As a broad-spectrum antiepileptic drug, lamotrigine is mainly used clinically for monotherapy or adjuvant therapy for partial and generalized seizures, and can also be used as an emotional stabilizer Type I bipolar disorder
    .

    Compared with classical antiepileptic drugs, lamotrigine is well tolerated, insignificant in enzyme induction and inhibition, and toxic during pregnancy Advantages
    such as less sex.
    In addition, lamotrigine is extremely effective for partial seizures and secondary generalized seizures, but it is less
    effective for primary generalized seizures.

    Lamotrigine was approved by the FDA in 1994 and approved for domestic marketing
    in 1999.
    In 2018, the global market sales of lamotrigine formulations, including all formulation dosage forms, were approximately $1.
    46 billion
    .
    With the expiration of patents, domestic generic drugs have gradually been approved for marketing, such as domestic Huahai Pharmaceutical
    .

    From the current situation, the domestic anti-epileptic drug market is still dominated by original imported products, but as generic drugs gradually grab the beach, the market share of original research brands is compressing
    .
    At present, China has about one-fifth of the world's epilepsy patients, but the treatment gap for domestic epilepsy patients is more than
    63%.
    This means that the domestic anti-epileptic drug market will be further enlarged in the future, and it is also a new opportunity
    for the development of domestic generic drug companies.

    Key References:

    Main References: Main References:

    1.
    "Novartis is going out of stock", Medicine Sra Plus, 2022-10-11

    1.
    "Novartis is going out of stock", Medicine Sra Plus, 2022-10-11

    2.
    The latest clinical diagnosis and treatment guidelines for epilepsy, Peking Union Medical College 2017,8(2-3):122

    2.
    The latest clinical diagnosis and treatment guidelines for epilepsy, Peking Union Medical College 2017,8(2-3):122

    3.
    Current status of epilepsy treatment and drug discovery, Acta Pharmaceutica Sinica, 10.
    16438/J.
    0513-4870.
    2020-1578

    3.
    Current status of epilepsy treatment and drug discovery, Acta Pharmaceutica Sinica, 10.
    16438/J.
    0513-4870.
    2020-1578

    4、Theodore WH,Spencer SS,Wiebe S,et a1. Epilepsy in north america:a report prepared under the auspices of the global campign against epilepsy, the international league against epilepsy and the world health organization[J]. Epilepsia,2006,47(10):1700_1722

    4、Theodore WH,Spencer SS,Wiebe S,et a1. Epilepsy in north america:a report prepared under the auspices of the global campign against epilepsy, the international league against epilepsy and the world health organization[J]. Epilepsia,2006,47(10):1700_1722
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.